Last updated on June 2018

Clinical Trial of Ultra-high Dose Methylcobalamin for ALS


Brief description of study

To examine the clinical efficacy and safety of ultra-high dose (50mg, im, twice a week) methylcobalamin in retarding the progression of symptoms in amyotrophic lateral sclerosis (ALS) patients, we enroll ALS patients diagnosed by revised-Awaji-El Escorial criteria within 12 months after the clinical onset. First they are followed for 12 weeks with Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised(ALSFRS-R) scores, and only those who exhibit drops of 1-2 points are allowed to enter into the test period. A total of 128 patients are randomized and the half having placebo. They are blindly evaluated for drops of ALSFRS-R in 16 weeks, as the primary outcome. After this, all subjects receive methylcobalamin.

Clinical Study Identifier: NCT03548311

Contact Investigators or Research Sites near you

Start Over

Masahiro Sonoo, MD

Teikyo University Hospital
Tokyo, Japan
3.39miles
  Connect »

Kazuaki Kanai, MD

Juntendo University Hospital
Tokyo, Japan
7.58miles
  Connect »